Halper Sadeh Investigates Mersana's Sale to Day One for Shareholder Rights Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2025
0mins
Source: PRnewswire
- Legal Investigation Initiated: Halper Sadeh LLC is investigating Mersana Therapeutics, Inc.'s sale to Day One Biopharmaceuticals, Inc. for potential violations of federal securities laws and breaches of fiduciary duties, aiming to protect shareholder rights and ensure the legality of the transaction.
- Cidara Transaction Analysis: Cidara Therapeutics, Inc. is being sold to Merck for $221.50 per share in cash, raising concerns about shareholder rights, with Halper Sadeh LLC potentially seeking increased compensation and additional disclosures to ensure transparency in the deal.
- Merger Impact Assessment: Ryerson Holding Corporation's merger with Olympic Steel, Inc. will result in Ryerson shareholders owning approximately 63% of the combined entity, prompting Halper Sadeh LLC to evaluate the potential impacts of this transaction on shareholder rights to safeguard their interests.
- Shareholder Rights Protection: Halper Sadeh LLC offers no upfront legal fees for consultations, encouraging shareholders to reach out to discuss their legal rights and options, ensuring they receive appropriate compensation and disclosures in the transaction.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
